JUTTA HOREJS-HOECK
Lifetime funding acquisition: approx. €2 900 000
| Funding period | Funding agency, grant ID and title |
| Current research projects | |
| 2021-2025 | Austrian Science Fund Grant ID: P33969 The NLPR3/eiF2 axis in AML |
| 2021-2023 | EVER Neuropharma Effects of NPepZn on the immune system |
| 2021-2023 | Cancer Cluster Salzburg, federal state of Salzburg CCS II-IOS, the microenvironment in acute myeloid leukemia |
| 2020-2024 | EU Horizon 2020 Grant ID: 956544 Directing the immune response through designed nanomaterials (DIRNANO) |
| 2019-2022 | EU Horizon 2020 Interreg V-A Italia-Austria (co-applicant, PI) Epigenetics in immunity and cancer (EPIC) |
| 2019-2022 | EU Horizon 2020 Grant ID: 812661 Quantitative detection of bacterial endotoxin by novel nanotechnological approaches (ENDONANO) |
| 2018-2022 | Austrian Science Fund Grant ID: W1213 NLRs in type 2 inflammation |
| — | — |
| Completed research projects | |
| 2017-2020 | Canster Cluster Salzburg Tumor-microenvironment in AML |
| 2017-2020 | Austrian Science Fund Grant ID: P29941 NOD1 controls tolerogenic DCs |
| 2016-2020 | EVER Neuropharma Anti-inflammatory effects of Cerebrolysin |
| 2014-2018 | Austrian Science Fund Grant ID: 25696 Signaling crosstalk between NOD2 and IL-31 |
| 2015-2016 | AAI Careers in Immunology Fellowship Grant ID: AI0615_P NOD1 counteracts anti-inflammatory effects mediated by IL-10 |
| 2011-2015 | Austrian Science Fund Grant ID: P23933 IL-31 regulates DC-mediated T cell responses in the course of atopic dermatitis |
| 2009-2013 | Austrian Science Fund Grant ID: P23933 The role of IL-31/IL-31R interactions in dendritic cells for the activation of human T cells |
Project participations
